EMA Recommends Extension of Indications for Acalabrutinib to Include the Treatment for Patients with MCL By Ogkologos - April 3, 2025 672 0 Facebook Twitter Google+ Pinterest WhatsApp New indication concerns the treatment of patients with relapsed or refractory mantle cell lymphoma Source RELATED ARTICLESMORE FROM AUTHOR The Legacy of the ESMO Patient Engagement Summit 2025: Advancing Rights of Patients with Cancer via Cross-Border Best Practices and Collaboration Sustained PFS Benefit of Imlunestrant Over SoC in Patients with ESR1-mutated Advanced Breast Cancer ESMO Welcomes Launch of Health Package Introducing EU Measures That Can Boost Innovation in Oncology and Help Prevent New Cancer Cases MOST POPULAR Camonsertib in Patients with Advanced Solid Tumours Harbouring Loss of Function... July 3, 2023 ¿Tener paneles solares o vivir cerca de una granja solar puede... April 6, 2023 COVID-19 Vaccines May Be Less Effective in Some People with Cancer May 26, 2021 GD2-CART01 May Induce Sustained Antitumour Effect in a Proportion of Patients... April 13, 2023 Load more HOT NEWS Colon capsule endoscopy – reshaping bowel cancer diagnosis Aggressive Prostate Cancer Subtype More Common Than Expected Five Questions With…Francisco. Death Rates from Ovarian Cancer will Fall in the EU and...
